Loading resource…

Sagar A. Patel, MD, MSc; Adithya K. Yadalam, MD, MSc; Marly van Assen, PhD; Stephanie M. Cantu, MD; Carlotta Onnis, MD; Bill Zheng, BS; Andee Koo, BS; Subir Goyal, PhD; Yuan Liu, PhD; Chang Liu, PhD, MPH; Nikhil T. Sebastian, MD; Vishal R. Dhere, MD;
The study aims to clarify the cardiovascular morbidity associated with ADT in prostate cancer patients, particularly the biological mechanisms underlying this relationship. Conducted at four centers in Atlanta, Georgia, the trial enrolled men with nonmetastatic prostate cancer undergoing pelvic radiotherapy. Participants were randomly assigned to receive either the GnRH agonist leuprolide or the GnRH antagonist relugolix over a duration of six months or longer. The primary outcome measured was the change in coronary artery total plaque volume.
No account needed